Total Payments
$782,116
2024 Payments
$187,665
Companies
25
Transactions
772
Medicare Patients
3,117
Medicare Billing
$455,569
Payment Breakdown by Category
Other$616,967 (78.9%)
Travel$90,859 (11.6%)
Consulting$57,608 (7.4%)
Food & Beverage$16,403 (2.1%)
Education$278.95 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $609,179 | 219 | 77.9% |
| Travel and Lodging | $90,859 | 252 | 11.6% |
| Consulting Fee | $57,608 | 43 | 7.4% |
| Food and Beverage | $16,403 | 231 | 2.1% |
| Honoraria | $7,788 | 7 | 1.0% |
| Education | $278.95 | 20 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $201,366 | 143 | $0 (2024) |
| Lilly USA, LLC | $165,166 | 210 | $0 (2024) |
| Gilead Sciences, Inc. | $79,260 | 59 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $58,696 | 47 | $0 (2024) |
| Helsinn Therapeutics (U.S.), Inc. | $55,055 | 53 | $0 (2019) |
| Daiichi Sankyo Inc. | $42,471 | 45 | $0 (2024) |
| Exelixis Inc. | $34,883 | 44 | $0 (2020) |
| PFIZER INC. | $27,113 | 33 | $0 (2024) |
| Merck Sharp & Dohme LLC | $26,680 | 28 | $0 (2024) |
| Stemline Therapeutics Inc. | $24,438 | 19 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $187,665 | 182 | AstraZeneca Pharmaceuticals LP ($60,131) |
| 2023 | $116,617 | 84 | AstraZeneca Pharmaceuticals LP ($42,244) |
| 2022 | $152,523 | 110 | AstraZeneca Pharmaceuticals LP ($54,460) |
| 2021 | $65,443 | 52 | AstraZeneca Pharmaceuticals LP ($37,766) |
| 2020 | $49,346 | 71 | Daiichi Sankyo Inc. ($16,915) |
| 2019 | $67,389 | 92 | Lilly USA, LLC ($33,679) |
| 2018 | $66,428 | 83 | Lilly USA, LLC ($20,631) |
| 2017 | $76,705 | 98 | Helsinn Therapeutics (U.S.), Inc. ($39,364) |
All Payment Transactions
772 individual payment records from CMS Open Payments — Page 1 of 31
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/18/2024 | Lilly USA, LLC | VERZENIO (Drug) | Travel and Lodging | Cash or cash equivalent | $71.91 | General |
| Category: Oncology | ||||||
| 11/18/2024 | Lilly USA, LLC | VERZENIO (Drug) | Food and Beverage | Cash or cash equivalent | $29.98 | General |
| Category: Oncology | ||||||
| 11/08/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Travel and Lodging | Cash or cash equivalent | $33.50 | General |
| Category: Oncology | ||||||
| 11/08/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Travel and Lodging | Cash or cash equivalent | $19.00 | General |
| Category: Oncology | ||||||
| 11/07/2024 | Lilly USA, LLC | VERZENIO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,500.00 | General |
| Category: Oncology | ||||||
| 11/07/2024 | Lilly USA, LLC | VERZENIO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,200.00 | General |
| Category: Oncology | ||||||
| 11/07/2024 | Lilly USA, LLC | VERZENIO (Drug) | Travel and Lodging | Cash or cash equivalent | $33.50 | General |
| Category: Oncology | ||||||
| 11/07/2024 | Lilly USA, LLC | VERZENIO (Drug) | Travel and Lodging | Cash or cash equivalent | $25.00 | General |
| Category: Oncology | ||||||
| 11/07/2024 | Lilly USA, LLC | VERZENIO (Drug) | Food and Beverage | Cash or cash equivalent | $23.76 | General |
| Category: Oncology | ||||||
| 11/07/2024 | Lilly USA, LLC | VERZENIO (Drug) | Food and Beverage | Cash or cash equivalent | $23.50 | General |
| Category: Oncology | ||||||
| 11/02/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $355.95 | General |
| 11/02/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $159.08 | General |
| 11/02/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $146.12 | General |
| 11/02/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $130.67 | General |
| 11/01/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,849.00 | General |
| Category: Oncology | ||||||
| 10/31/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,360.00 | General |
| Category: Oncology | ||||||
| 10/29/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Travel and Lodging | In-kind items and services | $219.24 | General |
| Category: Oncology | ||||||
| 10/29/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Travel and Lodging | In-kind items and services | $193.91 | General |
| Category: Oncology | ||||||
| 10/29/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $113.64 | General |
| Category: Oncology | ||||||
| 10/29/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Travel and Lodging | In-kind items and services | $109.35 | General |
| Category: Oncology | ||||||
| 10/29/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $21.87 | General |
| Category: Oncology | ||||||
| 10/23/2024 | Lilly USA, LLC | VERZENIO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,500.00 | General |
| Category: Oncology | ||||||
| 10/23/2024 | Lilly USA, LLC | VERZENIO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,200.00 | General |
| Category: Oncology | ||||||
| 10/21/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,360.00 | General |
| Category: Oncology | ||||||
| 10/19/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $315.34 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 794 | 1,097 | $418,647 | $117,236 |
| 2022 | 6 | 815 | 1,166 | $431,102 | $123,662 |
| 2021 | 7 | 763 | 1,186 | $410,157 | $126,830 |
| 2020 | 8 | 745 | 1,126 | $308,512 | $87,841 |
Total Patients
3,117
Total Services
4,575
Medicare Billing
$455,569
Procedure Codes
27
All Medicare Procedures & Services
27 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 391 | 523 | $179,389 | $47,858 | 26.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 116 | 281 | $129,318 | $39,393 | 30.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 128 | 128 | $83,649 | $22,735 | 27.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 55 | 55 | $12,870 | $2,966 | 23.0% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 89 | 90 | $10,981 | $2,425 | 22.1% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 15 | 20 | $2,440 | $1,860 | 76.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 416 | 571 | $190,143 | $52,041 | 27.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 105 | 289 | $129,472 | $41,988 | 32.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 133 | 133 | $83,923 | $21,974 | 26.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 67 | 67 | $15,209 | $3,372 | 22.2% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 18 | 29 | $3,422 | $2,183 | 63.8% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2022 | 76 | 77 | $8,933 | $2,104 | 23.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 379 | 670 | $216,410 | $64,874 | 30.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 80 | 178 | $77,430 | $26,823 | 34.6% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 106 | 106 | $64,978 | $19,485 | 30.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 125 | 137 | $30,140 | $7,037 | 23.3% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 27 | 48 | $5,520 | $3,827 | 69.3% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 29 | 29 | $14,239 | $3,802 | 26.7% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 17 | 18 | $1,440 | $982.03 | 68.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 227 | 530 | $163,770 | $45,385 | 27.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 287 | 342 | $71,136 | $16,437 | 23.1% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 47 | 47 | $27,307 | $8,126 | 29.8% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 57 | 57 | $26,790 | $7,230 | 27.0% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 76 | 97 | $7,760 | $6,017 | 77.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 22 | 22 | $9,108 | $2,673 | 29.3% |
About Dr. Nitin Rohatgi, M.D
Dr. Nitin Rohatgi, M.D is a Hematology healthcare provider based in Sacramento, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/07/2006. The National Provider Identifier (NPI) number assigned to this provider is 1235161621.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Nitin Rohatgi, M.D has received a total of $782,116 in payments from pharmaceutical and medical device companies, with $187,665 received in 2024. These payments were reported across 772 transactions from 25 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($609,179).
As a Medicare-enrolled provider, Rohatgi has provided services to 3,117 Medicare beneficiaries, totaling 4,575 services with total Medicare billing of $455,569. Data is available for 4 years (2020–2023), covering 27 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology
- Other Specialties Medical Oncology, Hematology & Oncology
- Location Sacramento, CA
- Active Since 07/07/2006
- Last Updated 08/17/2015
- Taxonomy Code 207RH0000X
- Entity Type Individual
- NPI Number 1235161621
Products in Payments
- VERZENIO (Drug) $144,115
- LYNPARZA (Drug) $96,244
- Trodelvy (Drug) $79,248
- ENHERTU (Biological) $65,552
- OPDIVO (Biological) $56,556
- AKYNZEO (Drug) $55,055
- Cabometyx (Drug) $34,883
- Enhertu (Drug) $33,403
- IBRANCE (Drug) $24,915
- Orserdu (Drug) $24,438
- KEYTRUDA (Biological) $22,282
- Nerlynx (Drug) $18,473
- KISQALI (Drug) $18,411
- ENHERTU (Drug) $9,068
- Halaven (Drug) $9,023
- Padcev (Drug) $5,224
- NERLYNX (Drug) $5,150
- LYNPARZA (Biological) $4,648
- Erleada (Drug) $3,417
- PADCEV (Biological) $1,635
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology Doctors in Sacramento
Dr. Mamta Parikh, M.d., M.s, M.D., M.S
Hematology — Payments: $34,877
Hematology $34,877
Dr. Samer Shihabi, M.d, M.D
Hematology — Payments: $4,770
Hematology $4,770
Dr. John Graff, Do, DO
Hematology — Payments: $1,227
Hematology $1,227
Dr. Kavya Babu, Md, MD
Hematology — Payments: $900.65
Hematology $900.65
Richard Young, Md, MD
Hematology — Payments: $98.96
Hematology $98.96
Dr. John Fisher, M.d, M.D
Hematology
Hematology